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Dr Verheyden and Dr Demanet
1 raised several interesting questions in their comment to our letter. 2 Following their suggestion, we additionally analyzed chronic myelogenous leukemia (CML) patients and their donors with regard to homozygosity for haplotype A and killer immunoglobuline-like receptor (KIR)1D to identify subjects lacking any functional activating KIR. In the respective groups, the frequencies were 25.8 and 16.1%. As this difference was not statistically significant, it may be hypothesized that the effect of activating KIRs is rather qualitative and restricted to KIR2DS4 while other activating KIRs do not appear to play a role. Indeed, the frequencies of KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1 were similar among CML patients and their donors. As well, the median sum of all activating KIRs was comparable (data not shown).
In our study, we used human leukocyte antigen (HLA)-matched bone marrow donors as a representative control group, considering that (i) HLA genotype is associated with the occurrence and the age-at-onset of CML 3, 4 and (ii) KIR-HLA ligand interactions appear to play a role in the pathogenesis of leukemia. 5 HLA-identical siblings constituted 32.3% of donors in a cohort of CML, 36.8% in acute myeloid leukemia and 33.3% in acute lymphoblastic leukemia (P ¼ NS). However, as suggested by Verheyden and Demanet, 1 we additionally looked at data available for the Polish population (I Nowak, E Majorczyk, P Kusnierczyk, unpublished data). Among 363 healthy individuals, 63.2% were KIR2DS4n001 À /KIR1D þ compared to 77.4% in our CML cohort (P ¼ 0.08).
We feel that our results on activating KIR2DS4 are complementary to those previously published by Verheyden et al., stressing the role of inhibitory KIRs. 5, 6 In both cases, there is rationale to verify the findings in large populations of patients with particular subtypes of leukemia.
B-chronic lymphocytic leukemia remains an incurable disease. Intensification regimens and hematopoietic stem cell (HSC) autografts are currently being tested to improve aggressive B-chronic lymphocytic leukemia control. Several trials have documented the difficulty of mobilizing HSC by granulocyte colony-stimulating factor after treatment with fludarabine (FDR), which is considered the most effective first-line treatment. This
Letters to the Editor negative effect on HSC egress appears to persist for several months after the last treatment cycle and could be correlated with circulating platelet levels. 1, 2 As previously reported, in vivo FDR-induced cytopenia suggests toxicity against hematopoietic progenitors (HPs). We postulated that FDR might impair two major cell components of the bone marrow niche, mesenchymal and hematopoietic cells.
Cell incubation with increasing doses of FDR showed a dosedependent toxicity for hematopoietic cells ( Figure 1a) ; only 44% of untreated cells were recovered at 10 mg/ml. Furthermore, we clearly observed a dose-dependent decrease in the frequency of all HPs, even greater than for Mono Nuclear Cells (MNCs), with recovery of only 33% of the control value at 0.1 mg/ml FDR, and around 1% at the highest dose. This indicated a preferential Letters to the Editor toxicity toward clonogenic progenitors (Figure 1b ) and suggested a possible relation with FDR capacity to inhibit DNA synthesis. Only few studies had reported an in vitro toxicity of FDR for colony-forming units (CFU) granulocyte-macrophage (CFU-GM). 3 Here, all myeloid progenitors, including erythroid burst-forming units (BFU-E) and CFU-megakaryocyte (CFU-MK), appeared sensitive to the drug (Figure 1c) . We also report, for the first time, a specific FDR dose-dependent effect against longterm culture initiating cell (LTC-IC), a population close to HSC, which nearly disappeared at the 1 mg/ml dose (Figure 1b) . However, because such functional in vitro assays involve a strong induction of cell proliferation, results should be interpreted with caution as in vivo a significant number of quiescent primitive progenitors likely remain protected from the effect of FDR. However, toxic effects at all stages of the hematopoietic hierarchy could partly explain the results of previous clinical studies showing that the dose-limiting toxicity of FDR involves myelosuppression, whereas nausea, vomiting and diarrhea are mild. 4 Similarly, mesenchymal cells (MCs), a key member of the hematopoietic niche, appeared specifically, highly and dose-dependently sensitive to FDR (Figure 1d ) with less than 30% cell recovery at the 0.03 mg/ml dose and as resistant to cyclophosphamide (data not shown). We and others have identified CD73, a molecule involved in FDR cell penetration and dephosphorylation 5 as a robust marker of mesenchymal progenitors. 6 We evaluated CD73 involvement using its specific inhibitor methylene adenosine di phosphate (MADP). No protective effect was noted, suggesting that CD73 is not actively involved in FDR toxicity toward MC (Figure 1d) . However, further studies are required to evaluate the role of other membrane transporters. Like HPs, the mesenchymal progenitors, detected as CFU-F, seemed to be preferential targets for the drug as colony size distribution showed a marked decrease in their frequency and in their proliferative capacity from the 0.3 mg dose (Figure 1d) . Interestingly, the toxic effect of FDR on MC never described until now, was transmissible to FDR-naive daughter cells, though with a dose-dependent impairment of their proliferative capacity (Figure 1e ). Surviving cells may present subtle biological impairment, probably corresponding to the modifications in their DNA sequence and/or repair mechanisms as suggested for quiescent chronic lymphocytic leukemia cells.
The action mechanism of granulocyte colony-stimulating factor is complex. However, the common target of these molecular systems is stromal cell-derived factor-1 (SDF-1), which, together with its ligand CXCR4, plays a major role in the mobilization/ homing process of HSC. As, to our knowledge, there is no satisfactory in vitro model of granulocyte colony-stimulating factor mobilization, we first studied the adherence of CD34 þ cells and their SDF-1-induced migration. After 1 h of cell contact, we observed no modification of the adherence properties of MNCs (Figure 2a) , whereas the adherence of total colony-forming cell (CFC), CFU-GM and BFU-E, was increased when using FDRtreated CD34 þ cells (Figure 2b ). This observation might reflect a modification in the relationship between progenitors and stromal cells or the selection of more resistant progenitors in the adherent population. Results of the transwell migration assay showed that the SDF-1-induced migration of CFC and LTC-IC was significantly impaired by FDR (Figure 2c ). Even if FDR may select resistant progenitors more sensitive to SDF-1, the strong decrease in SDF-1-induced mobilization of CD34 þ cells suggests a trend toward a bone marrow retention of surviving HPs. Unexpectedly, we Letters to the Editor detected no change in CXCR4, CD106 or CD49d expression on CD34 þ cells after contact with FDR or with FDR-preincubated MC (data not shown).
In conclusion, whereas clinical data argue for an hematopoietic and immune cell specificity of FDR, the scope of its action is larger than expected and involves endothelial, epithelial and nurse-like cells, 8 as well as MC as demonstrated here. Possible impairment of hematopoietic and stromal components might contribute to a certain extent to the myelosuppression observed in vivo, but also to the antileukemic effect of FDR in B-chronic lymphocytic leukemia, by modifying the environment of the B-cell clone. Furthermore, our surviving MC presented biological impairments that were transmissible to their progeny, thus accounting for the lasting effect observed in vivo. Moreover, FDR is able to modify or select HP so as to favor their retention in bone marrow, which could partly explain the reported impairment of in vivo HSC mobilization by granulocyte colony-stimulating factor alone. Besides, the residual toxicity observed on their mesenchymal progeny could explain the in vivo persistence of this effect. Understanding the mechanisms involved in FDR toxicity would make it possible to propose therapeutic strategies with less side effects.
